Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) insider Jason B. Shandell sold 56,996 shares of the stock in a transaction dated Monday, September 26th. The stock was sold at an average price of $19.50, for a total transaction of $1,111,422.00. Following the sale, the insider now owns 259,957 shares in the company, valued at approximately $5,069,161.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) opened at 19.57 on Thursday. Amphastar Pharmaceuticals Inc. has a 12-month low of $10.50 and a 12-month high of $21.53. The company has a market capitalization of $883.02 million, a PE ratio of 63.54 and a beta of 1.83. The stock has a 50 day moving average of $19.16 and a 200 day moving average of $15.70.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.22. The firm earned $68 million during the quarter, compared to analysts’ expectations of $62.10 million. Amphastar Pharmaceuticals had a net margin of 5.19% and a return on equity of 4.71%. The business’s revenue for the quarter was up 26.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.09) earnings per share. On average, equities research analysts predict that Amphastar Pharmaceuticals Inc. will post $0.37 EPS for the current year.
Several brokerages have commented on AMPH. Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 28th. Needham & Company LLC raised their price target on shares of Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, August 9th. Jefferies Group raised their price target on shares of Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Tuesday, August 9th. Piper Jaffray Cos. restated an “overweight” rating and issued a $23.00 price target (up previously from $22.00) on shares of Amphastar Pharmaceuticals in a research note on Wednesday, September 7th. Finally, BMO Capital Markets restated a “hold” rating and issued a $17.00 price target on shares of Amphastar Pharmaceuticals in a research note on Tuesday, August 9th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $20.00.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Acrospire Investment Management LLC boosted its position in Amphastar Pharmaceuticals by 57.5% in the second quarter. Acrospire Investment Management LLC now owns 6,791 shares of the company’s stock valued at $109,000 after buying an additional 2,479 shares during the period. Envestnet Asset Management Inc. bought a new position in Amphastar Pharmaceuticals during the first quarter valued at $115,000. C M Bidwell & Associates Ltd. bought a new position in Amphastar Pharmaceuticals during the second quarter valued at $207,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in Amphastar Pharmaceuticals during the first quarter valued at $180,000. Finally, Bank of Montreal Can bought a new position in Amphastar Pharmaceuticals during the second quarter valued at $292,000. Hedge funds and other institutional investors own 35.87% of the company’s stock.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.